Wuhan General Group Inc (WUHN)

[Warchest]

”Psilocybin has become a very promising candidate for future treatments for anxiety and depression because it appears to disrupt the sorts of engrained brain activity patterns that are the hallmark of those diseases.” Said Dr. Anna.

“Just like it took time for the regulators to get behind marijuana, we believe the same will happen with “magic mushrooms” in due course. We want to be far ahead of the curve and become pioneers in the market, collaborating with legislative bodies to help find better and healthier solutions,” added MJ MedTech CEO, Jeff Robinson.

The new division, M2BIO aims to develop new therapies that will help patients who suffer from mental illness and ease the burden on healthcare systems globally. This division will be exploring additional indications for psilocybin, with the goal of bringing new therapies to market in the years to come.